The Psychedelics as Medicine Report has revealed the industry is currently worth US$650 million (~£542 million), and is expected to exceed US$3 billion by 2026.
InsightAce Analytic has projected that the global psychedelic therapeutics market, valued at US$3.61bn in 2021, is expected to reach US$8.31bn (~£6.92bn) by 2028.
Research and drug development company Albert Labs has announced it will begin trading on the CSE.
Numinus Wellness received final approval from the Toronto Stock Exchange to graduate its listing to the TSX from the TSX-Venture Exchange.
UK-based psychedelics company Albert Labs has received conditional approval for the listing of its common shares on the Canadian Securities Exchange (CSE).
Levitee Labs has announced it has listed on the Frankfurt Stock Exchange (FSE).
Origin Therapeutics is poising for public listing on the Canadian Securities Exchange (CSE).
Awakn Life Sciences Corp.